Lori Sherer

Milliman is pushing the boundaries of actuarial modeling in collaboration with Microsoft Azure. In this new #MicrosoftStories article, you’ll hear from Patricia Renzi, Brian Fomby, FSA, MAAA, Amritpal Khangura about how our teams are leveraging high-performance computing and cloud-scale infrastructure to transform what’s possible. Together, we’re helping insurers run complex models more quickly, more reliably, and more affordability. Take a look at the full story by Geneviève Iezzoni learn what’s possible: https://bit.ly/3PoNAnI #Milliman #SolutionsforaWorldatRisk #Microsoft #Actuaries

32

2 Comments

LLMs are powerful tools—but not calculators. This article by William Nibbelin explains why actuarial use of LLMs requires external computational tools, validation frameworks, and careful workflow design to ensure results are reliable, traceable, and fit for decision-making based on the CAS Annual Meeting session by Xuan You, FCAS. #ActuarialReview https://lnkd.in/eETAWDNw

31

How can health equity move from talk to tangible strategy, and also become a growth engine? In our podcast, Oliver Wyman's Travis Kistler sits down with Sachin Jain, CEO of SCAN to discuss embedding measurable equity outcomes into strategy, designing products for underserved communities, and leading with what Jain calls “radical common sense.” They also examine the promise and the risks of AI in health care Listen to the full conversation and discover practical steps leaders can take today > https://owy.mn/3NX1RHL

4

1 Comment

Organizations embracing agentic AI report up to a 60% reduction in risk events, a 40% decrease in claim-handling times, and NPS improvements averaging 15 points across early pilots. These improvements don’t just happen by adding another bot. They require rethinking the operating model, embedding human oversight, and building platforms that can sense, decide, and act. Read about the full framework here: https://lnkd.in/gbM9jKPA #AI #AIAgents #Enterpriseplatforms

9

Excited to share BCG’s 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗧𝗿𝗲𝗻𝗱𝘀 𝟮𝟬𝟮𝟲 report co-authored alongside Margot Bleys, Bilal Khan, M.D., John Wu, and Priya Chandran Biopharma is operating under tighter constraints than in the past. Pricing and policy decisions are being pulled earlier in the value chain, geopolitical considerations are shaping where companies invest and partner, and manufacturing and commercialization have become core strategic considerations in a more fragmented post-pandemic landscape. BCG’s 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗧𝗿𝗲𝗻𝗱𝘀 𝟮𝟬𝟮𝟲 report explores what this means for how companies set priorities across R&D, business development, and operating models. Many of the choices management teams are making today will be difficult to unwind and will have a lasting impact on returns and competitive position. Read the full perspective here: https://lnkd.in/ekZ_UEFq

50